This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
First patients dosed in phase 2 platform clinical trial testing novel immunotherapy combinations in highly malignant ovarian cancer.
CRI’s latest analysis of the PD1/PDL1 immuno-oncology landscape confirms trends in trial design and patient enrollment, points to robust pipeline of new agents in clinical development
Four Key Scientists Behind the Vaccines to Share Virtual Stage at November 10 Event; Katalin Karikó, Ugur Sahin, Özlem Türeci, and Drew Weissman to Receive 2021 William B. Coley Award for Distinguished Research in Basic Immunology; Overdue Opportunity to Understand mRNA’s Origins and Future in Cancer Research
The first patients have enrolled in a platform clinical trial, called REVOLUTION, testing combination immunotherapy in patients with metastatic pancreatic cancer. The study uses an innovative design to test multiple combination therapies in parallel.
CRI's free and live online event for patients and caregivers covering cancer immunotherapy, clinical trials, and cancer care disparities takes place Oct. 7-8, 2021.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Immunotherapy clinical trials are critical endeavors that lead to breakthrough cancer treatments.
This Skin Cancer Awareness month, discover new research, treatments, and progress for a future immune to skin cancer.